In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


This content is currently on FREE ACCESS, enjoy another 1 days of free consultation

 

CMR in the evaluation of the results of percutaneous coronary interventions in patients with diabetes mellitus type 2 and chronic heart failure

Session Poster Session 3

Speaker Associate Professor Daniil Maximkin

Congress : Heart Failure 2019

  • Topic : heart failure
  • Sub-topic : Chronic Heart Failure: Comorbidities
  • Session type : Poster Session
  • FP Number : P1730

Authors : Y Rustamova (Baku,AZ), V Azizov (Baku,AZ), G Imanov (Baku,AZ), D A Maximkin (Moscow,RU), A Faibushevich (Moscow,RU)

Authors:
Y Rustamova1 , V Azizov1 , G Imanov1 , D A Maximkin2 , A Faibushevich2 , 1Azerbaijan Medical University, Internal Medicine - Baku - Azerbaijan , 2RUDN University - Moscow - Russian Federation ,

Citation:

Aim: to evaluate the effectiveness of PCI in patients with multivessel coronary disease and concomitant diabetes and chronic heart failure.

Methods: 102 patients were divided into 2 groups: group 1 (n=48) - patients with diabetes, and group 2 (n=54) - patients with coronary artery disease and heart failure without diabetes. Inclusion criteria: myocardial infarction in previously; angina II-III (CCS); silent ischemia; multivessel disease (SYNTAX score I <32); segments with abnormality local kinetic of the left ventricle; chronic heart failure I-III (NYHA); left ventricular ejection fraction (LVEF) is less than 45%. Visualization of post-infarction myocardial changes was performed using CMR, both before PCI and during the evaluation of long-term results. Primary endpoints: MACE (death, MI, repeated interventions).

Results: after 24 months, MACE in groups 1 and 2 was 10.4 and 8.1%, respectively (p=0.264). After PCI, in both groups there was a significant decrease a number of segments with abnormality local kinetic, compared with baseline data (p<0.05). In patients with diabetes, as well as in patients without diabetes, there is a significant increase in LVEF by as early as 12 months after PCI, as well as a decrease in end-diasystolic volume (EDV) and end-diasystolic size (EDS) of the left ventricle. A similar steady trend continues to 24 months of observation. The average data of the transmurality index in group 1 decreased, as compared with the pre-operative values, from 0.39±0.07 to 0.32±0.02. The average difference was 0.07 [0.02-0.08; 95% CI, p = 0.01]. In patients with diabetes, the number of pathological segments in the zone of hibernated myocardium directly correlates with the index of transmurality. The lower the transmurality index, the smaller the number of pathological segments detected and the better the recovery processes of dysfunctional myocardium occur. Unlike the index of trasmurality, the index of cardiac fibrosis does not correlate with the number of pathological segments in the hibernation zone. Factors associated with the development of MACE in patients with diabetes: HbA1c =6.5% to PCI, fasting plasma glucose =6.0 mmol / l, total cholesterol =5.2 mmol / l, triglycerides =1.7 mmol / l, LDL cholesterol =2.5 mmol / l. In addition, performing PCI after 30 days from myocardial infarction, as well as incomplete myocardial revascularization, SYNTAX score> 25, transmural index =0.45, cardiac fibrosis volume =45%, were also unfavorable risk factors for the development of MACE. At the same time, reduced LVEF was not a predictor of an unfavorable prognosis of PCI in such patients.

Conclusion: the frequency of MACE, as well as the dynamics of recovery of hibernated myocardium function, in patients with diabetes and chronic heart failure, is comparable to that in patients without diabetes mellitus. At the same time, the smaller the value of the transmurality index, the better the recovery processes of dysfunctional myocardium occur.



Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are